



Supplemental Data Fig. S1. Kaplan–Meier estimates of OS probability across 2016 WHO subgroups of MDS-EB and AML. (A, B) OS of patients with MDS-EB segregated by (A) the presence of *TP53* mutation (single or multi-hit) or *TP53* wild-type and (B) the presence or absence of multi-hit *TP53* alterations. (C) OS of patients with AML according to the presence of *TP53* mutations (single or multi-hit) or *TP53* wild-type. Annotated *P*-values are from log-rank tests comparing survival curves between groups. Abbreviations: OS, overall survival; MDS-EB, MDS with excess blasts.